临床肝胆病杂志2026，Vol.42Issue(7)：1551-1560,10.DOI:10.12449/JCH260710
卡瑞利珠单抗联合阿帕替尼治疗肝细胞癌临床应用专家共识
Expert consensus on clinical application of camrelizumab combined with apatinib in the treatment of hepatocellular carcinoma
中国临床肿瘤学会肝癌专家委员会 1中国临床肿瘤学会抗肿瘤药物安全管理专家委员会1
作者信息
摘要
Abstract
Camrelizumab combined with apatinib has been approved by the National Medical Products Administration(NMPA)as a first-line therapeutic regimen for hepatocellular carcinoma(HCC),and a wealth of clinical research evidence and practical experience associated with liver cancer has been accumulated to date.To guide the rational and effective clinical administration of camrelizumab combined with apatinib for HCC treatment,Expert Committee for Liver Cancer and Expert Committee on Safety Management of Anti-Tumor Drugs,Chinese Society of Clinical Oncology,jointly organized multidisciplinary experts and scholars specializing in liver cancer and related disciplines nationwide.This expert consensus has been formulated after thorough discussions and repeated revisions,in order to provide standardized and evidence-based clinical guidance for clinicians.关键词
卡瑞利珠单抗/阿帕替尼/癌,肝细胞/专家共识Key words
Camrelizumab for Injection/Apatinib/Carcinoma,Hepatocellular/Expert Consensus引用本文复制引用
中国临床肿瘤学会肝癌专家委员会,中国临床肿瘤学会抗肿瘤药物安全管理专家委员会..卡瑞利珠单抗联合阿帕替尼治疗肝细胞癌临床应用专家共识[J].临床肝胆病杂志,2026,42(7):1551-1560,10.
